Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

PURPOSE: Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic leukemia (CLL). We combined lenalidomide with rituximab to improve response rates in patients with relapsed or refractory CLL. PATIENTS AND METHODS: Fifty-nine adult patients (age 42 to 82 years) with...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Badoux, Xavier C., Keating, Michael J., Wen, Sijin, Wierda, William G., O'Brien, Susan M., Faderl, Stefan, Sargent, Rachel, Burger, Jan A., Ferrajoli, Alessandra
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2013
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878047/
https://ncbi.nlm.nih.gov/pubmed/23270003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.8623
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky